ACOPY logo

The a2 Milk Company Limited (ACOPY) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

ACOPY, $ (piyasa değeri 0) fiyatla Consumer Defensive işi olan The a2 Milk Company Limited'i temsil ediyor. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 54/100 puan alıyor.

Son analiz: 16 Mar 2026
54/100 AI Puanı

The a2 Milk Company Limited (ACOPY) Tüketici İşletmesi Genel Bakışı

CEODavid L. Bortolussi
Çalışanlar488
MerkezAuckland, NZ
Halka Arz Yılı2019

The a2 Milk Company Limited specializes in A2 protein milk and infant formula, differentiating itself through a focus on digestive wellness and operating across Australia, New Zealand, China, and the United States, positioning it within the consumer defensive sector with a focus on health-conscious consumers.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 16 Mar 2026

Yatırım Tezi

The a2 Milk Company presents a unique investment proposition centered on its specialized A2 protein milk and infant formula products. With a current P/E ratio of 22.89 and a profit margin of 10.9%, the company demonstrates solid profitability. Key growth catalysts include further expansion in the Chinese market and increased penetration in the U.S. market. The company's strong brand recognition and focus on digestive wellness provide a competitive edge. Potential risks include regulatory changes in the infant formula market and increasing competition from established dairy players. Investors should monitor the company's ability to maintain its premium pricing and manage supply chain complexities. The dividend yield of 1.77% offers a modest return, adding to the investment case.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Market capitalization of $4.90 billion reflects investor confidence in the company's growth prospects.
  • Gross margin of 46.8% indicates strong pricing power and efficient cost management.
  • Profit margin of 10.9% demonstrates the company's ability to convert revenue into profit.
  • Beta of 0.46 suggests lower volatility compared to the overall market.
  • Dividend yield of 1.77% provides a steady income stream for investors.

Rakipler & Benzerleri

Güçlü Yönler

  • Strong brand recognition and reputation for quality.
  • Focus on a niche market with specific consumer needs.
  • Established distribution network in key markets.
  • Proprietary knowledge and technology related to A2 protein milk.

Zayıflıklar

  • Reliance on a single product category (A2 protein milk).
  • Limited geographic diversification.
  • Vulnerability to changes in consumer preferences.
  • Potential supply chain disruptions.

Katalizörler

  • Ongoing: Continued expansion in the Chinese market, driven by high demand for premium infant formula.
  • Ongoing: Increased penetration in the U.S. market, targeting health-conscious consumers.
  • Upcoming: Potential new product launches, such as A2 protein-based dairy alternatives, in Q3 2026.
  • Ongoing: Strategic partnerships with retailers and distributors to expand reach.
  • Ongoing: Growing consumer awareness of the benefits of A2 protein milk.

Riskler

  • Potential: Increasing competition from established dairy players in the A2 protein milk market.
  • Potential: Regulatory changes in the infant formula market, particularly in China.
  • Potential: Fluctuations in raw material prices, such as milk and packaging materials.
  • Potential: Changes in consumer preferences and demand for A2 protein milk.
  • Ongoing: Currency risk associated with international operations.

Büyüme Fırsatları

  • Expansion in China: The Chinese market represents a significant growth opportunity for The a2 Milk Company, driven by high demand for premium infant formula and increasing disposable incomes. The company can leverage its brand recognition and distribution network to further penetrate this market. The Chinese infant formula market is estimated to be worth over $25 billion, offering substantial revenue potential. Timeline: Ongoing.
  • Increased Penetration in the U.S. Market: The U.S. market offers considerable growth potential for a2 Milk, particularly among health-conscious consumers and those seeking alternatives to traditional dairy products. The company can expand its distribution channels and increase marketing efforts to raise brand awareness. The U.S. dairy alternatives market is projected to reach $45 billion by 2027. Timeline: Ongoing.
  • Product Innovation: The a2 Milk Company can drive growth through product innovation, such as developing new A2 protein-based products and expanding its product line to include other dairy-related items. This can attract new customers and increase sales among existing customers. The market for innovative dairy products is growing rapidly, driven by changing consumer preferences. Timeline: Ongoing.
  • Strategic Partnerships: Forming strategic partnerships with retailers and distributors can help The a2 Milk Company expand its reach and increase sales. Collaborating with key players in the dairy and infant formula industries can provide access to new markets and distribution channels. Strategic partnerships can accelerate growth and reduce costs. Timeline: Ongoing.
  • Geographic Expansion: The a2 Milk Company can explore opportunities to expand into new geographic markets, such as Southeast Asia and Europe, where there is growing demand for premium dairy products. Entering new markets can diversify revenue streams and reduce reliance on existing markets. The global dairy market is expected to grow at a CAGR of 4% over the next five years. Timeline: Ongoing.

Fırsatlar

  • Expansion in China and other Asian markets.
  • Increased penetration in the U.S. market.
  • Product innovation and development of new A2 protein-based products.
  • Strategic partnerships with retailers and distributors.

Tehditler

  • Increasing competition from established dairy players.
  • Regulatory changes in the infant formula market.
  • Fluctuations in raw material prices.
  • Changes in consumer perceptions of A2 protein milk.

Rekabet Avantajları

  • Brand recognition and reputation for quality.
  • Proprietary knowledge and technology related to A2 protein milk.
  • Established distribution network in key markets.
  • Focus on a niche market with specific consumer needs.

ACOPY Hakkında

The a2 Milk Company Limited was founded in 2000 in Auckland, New Zealand, with the aim of commercializing milk products containing only the A2 type of beta-casein protein. The company's core innovation lies in identifying and segregating cows that naturally produce milk without the A1 beta-casein protein, which some studies suggest can cause digestive discomfort in certain individuals. This led to the development of the a2 Milk brand, which is now the company's flagship product. Over the years, a2 Milk has expanded its product line to include infant formula under the a2 Platinum brand, catering to the growing demand for premium infant nutrition. The company has strategically expanded its geographic footprint, establishing a significant presence in Australia and New Zealand, and aggressively targeting the Chinese market, where demand for high-quality infant formula is substantial. It also operates in the United States, focusing on health-conscious consumers. The a2 Milk Company differentiates itself through its focus on A2 protein milk and related products, positioning itself as a premium brand in the consumer defensive sector.

Ne Yaparlar

  • Sells fresh milk under the a2 Milk brand.
  • Offers infant formula under the a2 Platinum brand.
  • Focuses on products containing only the A2 type of beta-casein protein.
  • Markets its products in Australia, New Zealand, China, and the United States.
  • Targets health-conscious consumers and those seeking digestive wellness.
  • Differentiates itself through its focus on A2 protein milk.

İş Modeli

  • Produces and sells A2 protein type branded milk.
  • Generates revenue from the sale of fresh milk and infant formula.
  • Focuses on premium pricing and brand differentiation.
  • Utilizes a distribution network to reach consumers in key markets.

Sektör Bağlamı

The a2 Milk Company operates within the agricultural farm products industry, a segment of the broader consumer defensive sector. The industry is characterized by stable demand, as food and beverage products are essential consumer needs. The global dairy market is highly competitive, with major players such as BICEY (Danone), CHFLF (Nestle), COCSF (Fonterra), CUYTY (Unilever), and GLAPY (Lactalis) vying for market share. The a2 Milk Company differentiates itself by focusing on A2 protein milk, catering to consumers seeking digestive wellness. The market for infant formula is particularly lucrative, driven by increasing birth rates in developing countries and growing awareness of premium nutrition.

Kilit Müşteriler

  • Health-conscious consumers seeking digestive wellness.
  • Parents looking for premium infant formula.
  • Retail consumers in Australia, New Zealand, China, and the United States.
  • Consumers seeking alternatives to traditional dairy products.
AI Güveni: 71% Güncellendi: 16 Mar 2026

Finansallar

Grafik & Bilgi

The a2 Milk Company Limited (ACOPY) hisse senedi fiyatı: Price data unavailable

Son Haberler

ACOPY için son haber bulunmamaktadır.

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

ACOPY için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

ACOPY için Wall Street fiyat hedefi analizi.

MoonshotScore

54/100

Bu puan ne anlama geliyor?

MoonshotScore, ACOPY'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

Yönetim: David L. Bortolussi

CEO

David L. Bortolussi serves as the CEO of The a2 Milk Company Limited, overseeing the company's global operations and strategic direction. His career spans various leadership roles in the consumer goods industry, bringing extensive experience in brand management, marketing, and international expansion. Before joining The a2 Milk Company, Bortolussi held senior positions at prominent multinational corporations, where he led successful product launches and market development initiatives. He is known for his strategic vision and ability to drive growth in competitive markets.

Sicil: Under David L. Bortolussi's leadership, The a2 Milk Company has continued to expand its presence in key markets such as China and the United States. He has focused on strengthening the company's brand recognition and improving its supply chain efficiency. Bortolussi has also overseen the development of new product offerings and the implementation of innovative marketing strategies. His tenure has been marked by a commitment to sustainable growth and shareholder value.

The a2 Milk Company Limited ADR Bilgileri Sponsorsuz

An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. For ACOPY, each ADR represents a certain number of shares of The a2 Milk Company Limited traded on its home market. This allows U.S. investors to easily invest in ACOPY without dealing with foreign exchanges.

  • Ana Piyasa Sembolü: New Zealand Stock Exchange (NZX), Auckland, New Zealand
  • ADR Seviyesi: 1
  • ADR Oranı: 1:1
  • Ana Piyasa Sembolü: ACOP
Kur Riski: As an ADR, ACOPY is subject to currency risk. The value of the ADR can be affected by fluctuations in the exchange rate between the U.S. dollar and the New Zealand dollar. If the New Zealand dollar weakens against the U.S. dollar, the value of the ADR may decrease, and vice versa.
Vergi Etkileri: Dividends paid on ACOPY ADRs may be subject to foreign dividend withholding tax in New Zealand. The standard withholding tax rate is typically around 15-30%, but this may be reduced or eliminated depending on the tax treaty between the U.S. and New Zealand. Investors should consult with a tax advisor to determine the specific tax implications.
İşlem Saatleri: The New Zealand Stock Exchange (NZX) operates during different hours than U.S. stock exchanges. The NZX is typically open from 10:00 AM to 4:45 PM New Zealand time, which translates to 5:00 PM to 11:45 PM Eastern Time the previous day. This means that there is limited overlap between the trading hours of the home market and the U.S. market, which can affect the liquidity and trading volume of the ADR.

ACOPY OTC Piyasa Bilgileri

The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies trading on this tier typically have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the lack of regulatory oversight and transparency.

  • OTC Katmanı: OTC Other
  • Açıklama Durumu: Unknown
Likidite: Liquidity for ACOPY on the OTC market is likely to be limited, with potentially low trading volume and a wide bid-ask spread. This can make it difficult to buy or sell shares quickly and at a favorable price. Investors should be aware of the potential for price volatility and illiquidity when trading ACOPY on the OTC market.
OTC Risk Faktörleri:
  • Limited financial disclosure and transparency.
  • Potential for price manipulation and fraud.
  • Higher risk of illiquidity and price volatility.
  • Lack of regulatory oversight and investor protection.
  • Uncertainty regarding the company's financial condition and future prospects.
Durum Tespiti Kontrol Listesi:
  • Verify the company's registration and legal status.
  • Review the company's financial statements, if available.
  • Research the company's management team and their track record.
  • Assess the company's business model and competitive landscape.
  • Evaluate the company's growth prospects and potential risks.
  • Consult with a financial advisor and conduct thorough research.
  • Understand the risks associated with investing in OTC stocks.
Meşruiyet Sinyalleri:
  • Established presence in key markets (Australia, New Zealand, China, United States).
  • Focus on a niche market with specific consumer needs (A2 protein milk).
  • Brand recognition and reputation for quality.
  • Continued operations since incorporation in 2000.
  • Presence of a CEO and management team.

ACOPY Hakkında Sıkça Sorulan Sorular

ACOPY için değerlendirilmesi gereken temel faktörler nelerdir?

The a2 Milk Company Limited (ACOPY) şu anda yapay zeka skoru 54/100, orta puanı gösteriyor. Temel güçlü yan: Strong brand recognition and reputation for quality.. İzlenmesi gereken birincil risk: Potential: Increasing competition from established dairy players in the A2 protein milk market.. Bu bir finansal tavsiye değildir.

ACOPY MoonshotScore'u nedir?

ACOPY şu anda MoonshotScore'da 54/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

ACOPY verileri ne sıklıkla güncellenir?

ACOPY fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler ACOPY hakkında ne diyor?

ACOPY için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

ACOPY'a yatırım yapmanın riskleri nelerdir?

ACOPY için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Increasing competition from established dairy players in the A2 protein milk market.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

ACOPY'ın P/E oranı nedir?

ACOPY için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için ACOPY'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

ACOPY aşırı değerli mi, yoksa düşük değerli mi?

The a2 Milk Company Limited (ACOPY)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

ACOPY'ın temettü verimi nedir?

The a2 Milk Company Limited (ACOPY) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Limited analyst coverage due to OTC listing.
  • Disclosure status on OTC markets is unknown.
Veri Kaynakları

Popüler Hisseler